FDA Accepts sBLA for Bevacizumab in First-Line Ovarian Cancer

October 26, 2017 – The FDA has accepted a supplemental biologics license application (sBLA) for bevacizumab for the first-line treatment of advanced ovarian cancer, according to Genentech, the manufacturer of the angiogenesis inhibitor. If approved, the new indication would make frontline bevacizumab available in combination with carboplatin and paclitaxel, followed by bevacizumab alone, for women with advanced epithelial ovarian, fallopian tube, or primary … (leggi tutto)